Synapse - Works

Results (4073)

Prospective evaluation of alternative donor availability in 708 patients: Improved allograft access with enlarging CB inventory for all patients including racial and ethnic minorities

Meeting Abstract

Dahi, P. B.; Ponce, D. M.; Byam, C.; Devlin, S.; Lubin, M. N.; Evans, K. L.; Gonzales, A. M. R.; Sideroff, M.; Wells, D.; Giralt, S. A.; more...
Blood (2013)

Fulltext@MSK | Save

The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with elapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in all mantle cell lymphoma (MCL) patients

Meeting Abstract

Davids, M. S.; Seymour, J. F.; Gerecitano, J. F.; Kahl, B. S.; Pagel, J. M.; Wierda, W. G.; Anderson, M. A.; Rudersdorf, N. K.; Gressick, L. A.; Montalvo, N. P.; more...
Blood (2013)

Fulltext@MSK | Save

Drug-induced amyloidosis: A proteomic insight into 52 cases

Meeting Abstract

D'Souza, A.; Theis, J. D.; Vrana, J. A.; Dogan, A.
Blood (2013)

Fulltext@MSK | Save

Safe and effective re-induction of complete remissions in adults with relapsed B-ALL using 19-28z CAR CD19-targeted T cell therapy

Meeting Abstract

Davila, M. L.; Riviere, I.; Wang, X.; Bartido, S.; Stefanski, J.; He, Q.; Borquez-Ojeda, O.; Taylor, C.; Wasielewska, T.; Qu, J.; more...
Blood (2013)

Fulltext@MSK | Save

High-dose cytarabine monotherapy versus intermediate or high-dose cytarabine in combination with other agents as second-line salvage therapy In patients with acute myeloid leukemia who did not respond to initial induction therapy

Meeting Abstract

Dang, T. O. T.; Hilden, P.; Devlin, S. M.; Rampal, R. K.; Levine, R. L.; Berman, E.; Klimek, V. M.; Adel, N. G.; Tallman, M. S.
Blood (2013)

Fulltext@MSK | Save

Chemosensitization and mobilization of AML/ALL/MDS with plerixafor (AMD 3100), a CXCR4 antagonist: A phase I study of plerixafor + cytarabine and etoposide in pediatric patients with acute leukemia and MDS

Meeting Abstract

Cooper, T. M.; Baker, S. D.; Direnzo, J.; Trippett, T. M.; Gore, L.; Narendran, A.; August, K. J.; Absalon, M. J.; Boklan, J.; Pollard, J.; more...
Blood (2013)

Fulltext@MSK | Save

Results of a phase 2 randomized, open-label, study of lower doses of quizartinib (AC220; ASP2689) in subjects with FLT3-ITD positive relapsed or refractory acute myeloid leukemia (AML)

Meeting Abstract

Cortes, J. E.; Tallman, M. S.; Schiller, G.; Trone, D.; Gammon, G.; Goldberg, S.; Perl, A. E.; Marie, J. P.; Martinelli, G.; Levis, M.
Blood (2013)

Fulltext@MSK | Save

Phase 1 trial of carfilzomib + high dose melphalan conditioning regimen prior to autologous hematopoietic stem cell transplantation (AHSCT) for relapsed multiple myeloma

Meeting Abstract

Costa, L. J.; Landau, H.; Venkata, J. K.; Kang, Y.; Koehne, G.; Chung, D. J.; Lendvai, N.; Bentz, T.; Giralt, S.
Blood (2013)

Fulltext@MSK | Save

MAGE-A3 recombinant protein (recMAGE-A3) immunotherapy and autologous peripheral blood lymphocyte (PBL) infusion is safe and induces robust humoral immune responses in multiple myeloma (MM) patients undergoing autologous stem cell transplantation (autoSCT)

Meeting Abstract

Cohen, A. D.; Lendvai, N.; Gnjatic, S.; Jungbluth, A. A.; Bertolini, S.; Pan, L.; Venhaus, R.; Tsakos, I.; Garcia, K.; Thibodeau, L.; more...
Blood (2013)

Fulltext@MSK | Save

Clinical activity of idelalisib (GS-1101), a selective inhibitor of PI3Kδ, in phase 1 and 2 trials in chronic lymphocytic leukemia (CLL): Effect of del(17p)/TP53 mutation, del(11q), IGHV mutation, and NOTCH1 mutation

Meeting Abstract

Coutre, S. E.; Leonard, J. P.; Barrientos, J. C.; De Vos, S.; Flinn, I.; Furman, R. R.; Brown, J. R.; Wagner-Johnston, N.; Benson, D. M. Jr; Schreeder, M. T.; more...
Blood (2013)

Fulltext@MSK | Save